CurrentBody Skin LED Face Mask Review: An Effective Tool For Skin Renewal
In our testing, we found the CurrentBody Skin LED Light Therapy Face Mask Series 2 helped with ... More overall glowiness and evening tone.
At $470, this product is an investment; still, it's far less expensive than costly in-office treatments, and far more convenient because I can wear it while in bed or on the couch. It requires 10 minutes of use three to five times per week. After using it for two weeks (and ongoing testing), I can already see noticeable results. If you're looking to improve skin dullness, decrease redness from conditions like acne or rosacea, or minimize the look of smile lines and crow's feet, the CurrentBody LED face mask is a worthwhile pick.
Amazon
Light modes: Red, near-infrared and deep near-infrared | Skin concerns: Fine lines, wrinkles, hyperpigmentation, dullness | Wireless: Yes (with connected controller) | Number of LEDs: 263 | Usage: 10 minutes, three to five times per weekBest for:
Skip if:
This FDA-cleared device is wireless and powered by a rechargeable controller, which is slightly smaller than the length of a smartphone. You wear it for pre-programmed 10-minute treatments from three to five times per week. 'LED mask therapy is best suited for skin concerns related to inflammation, healing and aging,' says board-certified dermatologist Dr. Rhonda Q. Klein at Modern Dermatology. The CurrentBody mask works to brighten the skin, reduce the appearance of fine lines, improve texture and tone, decrease redness, and enhance collagen production. It features 236 LED lights and is comprised of red (633nm), near-infrared (830nm) and deep near-infrared (1072nm) wavelength bulbs. Red light targets fine lines and wrinkles, while also increasing collagen production. Near-infrared light is said to energize cells, firming, tightening and brightening the skin. Deep near-infrared light is designed to penetrate even deeper into the skin to help boost collagen production.
Compared to other LED devices on the market (our team evaluated the best LED face masks), the CurrentBody Series 2 LED face mask features a larger number of LED bulbs than many others, and it offers more focused treatment than the first-generation device. The mask is made from 'liquid' silicone, which is soft and comfortable to wear, and it flexes and molds easily to the face when the straps are tightened. This version has a new chin section to provide full face coverage—and to address an often-neglected treatment area. It also has 16 deeply penetrating deep near-infrared lights placed around the mask's eyes and mouth—an area of particular concern for many people—to help enhance results.
The CurrentBody LED Face Mask Series 2 features 263 LED lights in three different wavelengths—red, ... More near-infrared and deep near-infrared.
One thing that makes LED masks a popular beauty device is their efficacy. According to the brand's eight-week clinical study, the CurrentBody LED face mask treatments resulted in improvement of skin elasticity by 57% and a more radiant and youthful appearance. It reduced wrinkles by 30%, specifically causing forehead lines to appear softer. Skin tone brightness and skin firmness both significantly improved during that time, as did outer eye wrinkles and nasolabial folds, which decreased by more than 20%.
Setting up the CurrentBody LED face mask was straightforward. The instructions specified that the device should be charged for 4.5 hours (to reach a full charge) before use, which I did. Once it was ready to use, attaching the hook-and-loop closure straps to the mask took just a couple of minutes. The device has both a behind-the-head closure and a strap on top of the head for a secure fit.
Because mornings are typically rushed in my house, I preferred to use the CurrentBody device at night. I began by washing my face and patting it completely dry with a towel before putting on the mask for the ten-minute session while relaxing in bed. I liked that it's preset to turn off after the ten-minute treatment, so I didn't have to worry about setting a timer. It also has a clip-on controller and is otherwise cordless, which was nice in case I wanted to get up and move around.
The CurrentBody LED Face Mask Series 2 has elastic straps that fit behind and on top of your head to ... More keep the mask securely in place whether you're sitting or moving around.
During testing, the mask felt pleasantly warm on my face, but not hot. The included black eye inserts helped shield my eyes from LED light if I opened them, although I preferred to keep them shut while it was on. The mask had a lightweight feel, and it was easy to adjust the straps in the back so the whole thing wouldn't get jostled. However, the mask only sat flush with the skin on my forehead, around my eyes and on my upper cheeks; there was a slight gap between it and the skin on my lower jaw and chin. I have a more pronounced bridge on my nose, so the mask would become slightly uncomfortable and leave a small mark at the top of my nose by the end of the treatment, which would fade after a few minutes. After use, I wiped the inside of the mask with a slightly damp microfiber cloth, as I found that the mask attracted lint easily on both sides.
I wore the mask eight times over two weeks, and I will continue to do so for several months. Although it has only been a short period, I have noticed an overall brightening of my skin since wearing it. I'm hoping it will help decrease hyperpigmentation, even out my skin tone overall and reduce the small parentheses lines around my mouth.
In the relatively brief period that I've been using the mask, I've noticed overall skin brightening and a slight reduction in redness, meaning my face looks a little more even and filtered without needing to apply makeup. Even with limited use so far, I feel that this is a worthwhile investment, especially since it's easy to use and comfortable to wear. Additionally, editors on our team tested this CurrentBody LED face mask over more than a month. According to one tester, 'my skin tone appears a little more even, brighter, and some sun spots I have on my forehead seem to have faded.' Another says, 'I feel like my skin tone has evened out, and I feel a little more glowy and less like I have winter 'blah' skin.' Because clinical data also supports this device's efficacy, I feel confident that it will continue to produce visible results over time.
I'm a longtime magazine writer and editor who has extensive experience covering lifestyle topics. When it comes to beauty, I've written about and tested the best skincare for women over 50 and shampoos for color-treated hair and the best microcurrent devices, among many other stories. My first experience with red light therapy was when I tested the Therabody Theraface Pro, a versatile facial treatment tool that also has red light therapy. After a brief testing period using the CurrentBody LED Light Therapy Face Mask Series 2, I can already see a difference in my skin tone and brightness. I also reviewed testing data from our panel of testers to incorporate their experiences with the device.
This assignment was assigned and edited by deputy editor Jane Sung, who oversees the beauty and grooming vertical. She's covered beauty and lifestyle topics for over two decades and has produced numerous skincare stories and tested reviews like the best LED face masks roundup, best at-home laser hair removal devices and more. I also interviewed board-certified dermatologist Dr. Rhonda Q. Klein of Modern Dermatology for her expert insights.
The brand recommends using the device for 10 minutes a day from three to five times per week for optimal results. Of course, like with most beauty devices, consistent use is key.
Yes, the CurrentBody LED Light Therapy Face Mask Series 2 is FDA Cleared. This means that the Food and Drug Administration (FDA) has reviewed the device and deemed it safe and effective for use for its intended purpose. FDA approval typically requires additional, more rigorous testing.
'At-home LED devices can truly deliver results—but only if you're willing to commit to consistent, long-term use,' says dermatologist Dr. Rhonda Q. Klein. 'These treatments are proven effective when used properly and regularly.' To maximize your investment, Klein suggests looking for an FDA-cleared device with third-party clinical data supporting its claims. 'Focus on devices that use a variety of wavelengths, as this variety is most effective,' she says. 'The CurrentBody Series 2 includes 236 diodes for coverage all over the face and the LEDs emote the 3 most clinically studied wavelengths for anti-aging; red light (633nm), near-infrared (830nm) and deep near-infrared (1072nm) which delivers the treatment across the deep and more surface level layers of the skin.'
Benefits of using an LED face mask depend on continual, consistent use. 'It's not a set-it-and-forget-it treatment,' says Klein. 'This is a long-term ritual that needs to be used on an ongoing basis to achieve and then maintain results.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Seniors swear by this 'effective and safe' anti-slip bath mat to help prevent falls in the shower — it's 43% off ahead of Prime Day
It only takes a quick second to fall and injure yourself, which is why it's essential to prevent unnecessary slips. According to HealthLink BC, thousands of older adults fall and hurt themselves every year. The organization recommends installing non-skid mats inside your shower or tub to help prevent unexpected injuries. The Gorilla Grip Patented Bath Mat is currently 43 per cent off as part of Amazon's early Prime Day deals — bringing the price down to $23. It has more than 86,000 ratings, and shoppers say it's "effective and safe." If you're interested, keep scrolling to see more about the deal and what customers have to say about the product. This mat helps prevent slips in the shower and has a 4.5-star rating on Amazon and more than 86,000 reviews. This textured, plastic bath mat has hundreds of suction cups that adhere to the bottom of your tub and shower to keep it firmly in place. It also has dozens of drainage holes that easily allow water to flow under the mat, helping to prevent stagnant water from sitting on the mat and in your tub. The mat itself is 35 x 16 inches, and it comes in 20 different colour options, including transparent and opaque choices. If it's starting to look a little dirty, all you need to do is throw it in your washing machine and then let it air dry. ⭐ 4.5/5 stars 🛍️ 86,000+ reviews 🏅"This bath mat is fantastic. It grips the tub securely to avoid slipping." $23 $40 at Amazon Someone called the product the "best shower mat ever" and said they'd repurchase it if needed. Another said it's "incredibly effective" and shared it has a "cushion-like feeling." Other shoppers also said it's "comfy on the feet" and also comfortable to sit on, noting they "feel much safer" when dealing with the slippery surfaces. However, some users say it could use "a little more padding," while others say the size is awkward for their particular shower or tub — all things to keep in mind before purchasing. With more than 86,000 reviews, shoppers say this Amazon's Choice bath mat is comfortable and effective. Most importantly, it makes them feel safer in the shower and helps prevent shower- and bath-related injuries. However, be sure to take down the measurements of your tub or shower before ordering.
Newsweek
44 minutes ago
- Newsweek
Health Insurance CEO Pulls Back Curtain on Prior Auth Reform
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox. To commemorate the Fourth of July weekend, I have an American story for you. It's got all the Stars and Stripes: entrepreneurial spirits, bootstraps mentalities and the familiar drag of bureaucracy. For the past several months, I've been working on this feature story about how patient advocacy groups are changing the pace of health care, working to find and fund cures for their loved ones' rare diseases (and, in some cases, their own). What I found was a community of ordinary people doing extraordinary things—not because they had the time, training or resources, but because they had no other choice. Parents, spouses and patients have taken on roles once reserved for pharmaceutical executives and lab directors, plunging headfirst into grant writing, data sharing and even drug development. These patient advocates are becoming increasingly important to the field of rare disease research, Dr. Dominique Pichard, director of the NIH's National Center for Advancing Translational Sciences' (NCATS) division of rare disease research and innovation, told me. Less than 5 percent of known rare diseases have an FDA-approved treatment available. Research efforts tend to focus on impacting the most lives with the fewest resources, as grant funding is competitive and hard to come by. But this means that many rare diseases are left untouched. Conditions that impact fewer than 200,000 Americans are difficult to lobby for—and those that do garner attention still face challenges when looking to establish expert advisory panels or fill a clinical trial. That's where patient advocacy groups come in, compiling data, educating providers and serving as connectors between small populations and large research institutions. In some cases, their efforts have helped fast-track clinical trials. In others, they've secured the first-ever FDA-approved treatment for a rare disease. But while their success stories are remarkable, they also raise bigger questions: Should patients be expected to do this much? Should finding a cure for a devastating condition depend on how many calls a parent is willing to make or whether they can raise $5 million? "[This work] is really important, but it has also created a pressure on families," Pichard said. "They feel like selling their assets, quitting their jobs and learning science is the only way [their] child can get a cure." This piece explores that bittersweet tension between the promises and pressures of patient-led progress. I hope you'll give it a read this holiday weekend, and maybe share it with someone who, like the advocates featured, refuses to take "no" or "slow" for an answer. Essential Reading The FBI has uncovered $14.6 billion worth of fraudulent claims submitted to Medicare, Medicaid and other government health care programs , the agency said on Monday in conjunction with the Department of Justice (DOJ). The investigation resulted in 324 defendants being charged, including 96 medical professionals. , the agency said on Monday in conjunction with the Department of Justice (DOJ). The investigation resulted in 324 defendants being charged, including 96 medical professionals. Now, the DOJ, FBI and HHS say they are collaborating to create a health care data fusion center that will help them identify, investigate and prosecute health care fraud. that will help them identify, investigate and prosecute health care fraud. And yesterday, the entities announced a DOJ-HHS False Claims Act Working Group, in which HHS will refer potential False Claims Act violations to the DOJ. Read more about the working group, its members and its goals here. Microsoft AI unveiled new research demonstrating AI's abilities in sequential diagnostics. The company's new model-agnostic MAI Diagnostic Orchestrator (MAI-DxO) achieved 85.5 percent diagnostic accuracy—outperforming generalist physicians, who reached the correct diagnosis 20 percent of the time, on average. The company's new model-agnostic MAI Diagnostic Orchestrator (MAI-DxO) achieved 85.5 percent diagnostic accuracy—outperforming generalist physicians, who reached the correct diagnosis 20 percent of the time, on average. The study has its limitations. Microsoft's panel of 21 U.S. and U.K. doctors had a median of 12 years of experience but were not allowed to use search engines, language models or other sources of medical information when interacting with SDBench. These tools are common in physicians' practices, with about 1 in 5 using generative AI and about 7 in 10 using search engines on a regular basis, according to recent research—so the human participants may have achieved higher diagnostic accuracy if allowed to access their typical suite of online resources. The report received mixed reviews, generating significant hype in the digital health care space but receiving pushback from skeptical physicians. I spoke with Microsoft AI CEO Mustafa Suleyman and Health Vice President Dr. Dominic King about the research ahead of its release. Get the exclusive scoop here. The Joint Commission has launched "Accreditation 360," a project it says will set a "new standard" for health care accreditation —using data analytics to fine-tune its focus on benchmarking and outcomes. The reforms include an updated accreditation manual, a new certification program, and moves to improve transparency and streamline processes. The organization has removed 714 requirements from the hospital accreditation program. Read all about The Joint Commission's dive into the digital era here, featuring exclusive insights from President and CEO Dr. Jonathan Perlin. —using data analytics to fine-tune its focus on benchmarking and outcomes. The reforms include an updated accreditation manual, a new certification program, and moves to improve transparency and streamline processes. The organization has removed 714 requirements from the hospital accreditation program. Read all about The Joint Commission's dive into the digital era here, featuring exclusive insights from President and CEO Dr. Jonathan Perlin. Read all about The Joint Commission's dive into the digital era here, featuring exclusive insights from President and CEO Dr. Jonathan Perlin. The Senate voted to advance President Donald Trump's One Big Beautiful Bill (H.R. 1) on Tuesday, approving nearly $1 trillion in proposed Medicaid cuts that would revoke health care coverage from at least 11.8 million Americans over the next decade. (H.R. 1) on Tuesday, approving nearly $1 trillion in proposed Medicaid cuts that would revoke health care coverage from at least 11.8 million Americans over the next decade. The House Rules Committee advanced the Senate's proposed changes, andat the time of writing on Wednesday afternoon, House Republicans were gunning to approve the final version by July 4. In an opinion piece for The New York Times, Larry Levitt, executive vice president for health policy at KFF, wrote: "This Republican policy bill is effectively a partial repeal of the Affordable Care Act to help pay for tax cuts, and should it reach President Trump's desk, it would represent the biggest rollback in federal support for health coverage ever." Pulse Check Paul Markovich is the president and CEO of Ascendiun. Paul Markovich is the president and CEO of Ascendiun. BCBS Paul Markovich is the president and CEO of Ascendiun, the nonprofit, ultimate parent company of Blue Shield of California, Blue Shield Promise Health Plan, Altais and Stellarus. He previously served as CEO of Blue Shield of California from 2013 to the end of 2024 and currently sits on the boards of the Blue Cross Blue Shield (BCBS) Association and America's Health Insurance Plans (AHIP). On Tuesday, I connected with Markovich to discuss last week's prior authorization reforms, born from a roundtable with health insurance companies and backed by HHS and CMS. Editor's Note: Some responses have been lightly edited for length and clarity. AHIP and BCBS were involved in these reforms, and you sit on the boards of both. From your perspective, when did these conversations about changing the prior authorization process really begin? They've been going on for probably the better part of a year behind the scenes with both trade groups. The plan was to develop these criteria and then go out and publicly announce them, but we [decided] we would love to get some positive feedback and support from the federal government. In particular, the Centers for Medicare and Medicaid Services is a pretty big customer and client on this one. So we went to them and said, "Look, this is what we've come up with. This is what we're planning on doing. A, How do you feel about it? And B, Would you be willing to say you feel good about it in public?" And they said, "You know what? We really like this, and before you go public, let's talk about this in more detail, and go out effectively together and talk about these changes." That ultimately led to the announcement, but it was very much conceived and driven by the trade associations for the health plans. The prior authorization process has been debated by physicians, hospitals, health plans and even the government for a number of years. What about this particular moment made it time to act and lean into reform? It was really clear this was our top pain point with patients, with the physician community and hospitals as well. This was the thing that was causing the most frustration and friction in the system. There was the sense that the status quo was problematic, and that at some point there would probably be a solution, or solutions that were developed. Then the question would be, who was going to develop them, and where was [reform] going to come from? Was it going to come from the federal government, state governments? All of those were possibilities. And I think we all just recognized we can do a whole lot better than this, and we need to do a whole lot better than this—and we can either construct something that we feel would be impactful without being detrimental, or we can wait for someone else to develop a solution which might be impactful but could also be detrimental, depending on how it's crafted. There have been various events along the way, various ups and downs in the political process, but eventually, this was too painful of a point to be left alone. One of the reforms laid out in the pledge is the standardization of electronic prior authorization submissions. What has been holding up the digitization process, and what will be the greatest challenge going forward? One of the biggest barriers to getting there—and it is going to be our biggest challenge going forward—is establishing and adopting standards for the real-time digital exchange of the information. And I know this from personal experience, because I've been a champion of creating a comprehensive digital health record for every American for many years. We managed to get a law passed in California that requires the sharing of data from physicians and hospitals to health plans: so we have actually created for our members a comprehensive, real time digital record in California, but it's in part thanks to that law and the requirement to share the data. But what ends up happening most of the time in prior authorizations is the health plan will say, there are certain best practices in health care that have been researched, that clinicians agree upon. There's a consensus about what the model of care should be in this situation, and what [the provider is] proposing to do is not consistent with that. But typically what happens is you [as a health plan] don't have all the information on the member. It's there in the medical record somewhere, but it hasn't been sent to the plan in a format that they need to say, "Yes, I can match this up. This patient has this diagnosis. Yes, their test results would indicate that they need this procedure or this drug. It's consistent with medical protocols." So typically, we're missing information, and then a series of time (days, sometimes ) that goes by where we're faxing requests for information. That's been the biggest challenge in the pre-authorization process. When we announced as a plan back in the fall of last year (before these industry announcements) that we were going to a real-time digital solution for prior authorization, we did a little spoof video with me bashing the fax machine to smithereens, which you may find entertaining. To me, that's the biggest thing, Alexis. It's getting standards and protocols down, getting that data available. How is it that the health plan can access that information on the patient, from the physician and hospital, and more broadly, from all of the care that they've had in their history of care? If we have access to all of that, there's absolutely no reason why these prior authorization decisions can't happen as quickly as your prior authorization decisions do on your credit card, and that's what we're shooting for. But what needs to happen is that digitization of the data and that real time sharing of it—and there's been challenges with that, historically. C-Suite Shuffles Oregon Health & Science University tapped Dr. Shereef Elnahal to serve as its sixth president after a lengthy national search. Previously, Elnahal was appointed by President Joe Biden as undersecretary for health at the VA. tapped to serve as its sixth after a lengthy national search. Previously, Elnahal was appointed by President Joe Biden as undersecretary for health at the VA. Debra Jaeger is the first chief revenue officer at Mount Sinai , based in New York City. In the role, she'll be responsible for integrating revenue cycle operations across the health system, reducing variation in processes and eliminating silos. is the first at , based in New York City. In the role, she'll be responsible for integrating revenue cycle operations across the health system, reducing variation in processes and eliminating silos. Rich Liekweg is retiring from his role as CEO of BJC Health System on October 1. Liekweg joined the St. Louis-based health system in 2009 and assumed the top role in 2018. He was instrumental to the health system's growth and oversaw its 2024 merger with Saint Luke's Health System in Kansas City. Nick Barto, current president of BJC, will succeed Liekweg. Executive Edge Dr. Jeffrey Giullian is the chief medical officer of DaVita Kidney Care. Dr. Jeffrey Giullian is the chief medical officer of DaVita Kidney Care. DaVita Dr. Jeffrey Giullian is the chief medical officer of DaVita Kidney Care, which provides kidney care and dialysis services across the nation and works to transform the experience of the more than 35 million people in the U.S. that live with chronic kidney disease (CKD). Giullian has been busy at DaVita, which is growing its value-based care arrangements and expanding access to kidney transplantation. (Last year, more than 8,200 DaVita patients received a kidney transplant, the company's highest number of annual transplants to date.) He also lives a full life outside of work, serving in an advisory capacity at the University of Colorado and the Denver Business School, and preparing to be an empty-nester when his daughter begins college at UCLA this fall. For this week's Executive Edge, I connected with Giullian to learn how he juggles it all: "Prioritizing health and wellness is something I take seriously—not just because of the demands of my role, but because I believe it's foundational to showing up as my best self, both professionally and personally. One of the ways I stay grounded is through running . It's a consistent part of my routine that gives me space to reflect, recharge, and maintain physical and mental clarity. . It's a consistent part of my routine that gives me space to reflect, recharge, and maintain physical and mental clarity. "I also try to be intentional about how I spend my time outside of work. With my daughter preparing for college, my wife and I are focused on making the most of this chapter as a family. That means carving out time for meaningful experiences, even amid a full calendar. I've found that when I align my personal time with what matters most—family, movement and purpose-driven work—it becomes easier to maintain energy and perspective. "Wellness, to me, isn't just about physical health. It's also about staying connected to a sense of purpose. When I feel aligned with the work I'm doing and the values I hold, I'm more energized, more present and more resilient in the face of challenges. That sense of purpose acts as a compass. It helps me make decisions about where to invest my time and energy, and it keeps me grounded when things get busy. Whether I'm contributing to meaningful change in health care or showing up for the people who matter most in my life, I've found that fulfillment comes from knowing that my actions are part of something larger." This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
Yahoo
an hour ago
- Yahoo
Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505
Schrödinger, Inc. (NASDAQ:SDGR) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Schrödinger, Inc. (NASDAQ:SDGR) announced that its investigational drug SGR-1505 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of adults with Waldenström macroglobulinemia who have not responded to at least two prior therapies, including a Bruton's tyrosine kinase (BTK) inhibitor. The designation is designed to expedite the development and review of drugs that address serious or life-threatening conditions with unmet medical need. A biopharmaceutical executive discussing plans with a government laboratory. SGR-1505 is a selective MALT1 inhibitor currently in clinical development. Waldenström macroglobulinemia is a rare type of non-Hodgkin lymphoma, and treatment-resistant forms present significant challenges for patients and clinicians. Schrödinger's approach to drug discovery gives it a unique advantage in targeting such difficult diseases. The company is best known for its computational platform that integrates physics-based modeling and advanced algorithms to design novel compounds with greater precision and efficiency. This model-driven strategy makes Schrödinger one of the few healthcare companies at the forefront of computational drug discovery—a field that blends molecular science with cutting-edge software to identify and optimize potential therapies faster than traditional methods. With the FDA's Fast Track status, SGR-1505 may benefit from more frequent interaction with the agency and potential eligibility for accelerated approval, positioning Schrödinger to advance an important treatment option while reinforcing its growing role as a technology-driven innovator in the pharmaceutical sector. While we acknowledge the potential of SDGR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SDGR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
